TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06164275
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06164275
Drug: Vinblastine
Normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05929339
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin
Study: NCT05162742
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATC: M04AC01
Study: NCT04824794
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab is administered by SC injections.
Study: NCT05894239
Drug: Inavolisib
Normalized name: Inavolisib
DrugBank: Inavolisib (DB15275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive an inavolisib tablet to be taken orally (PO), once a day (QD), on Days 1-21 of each 21-day cycle, beginning on Day (D) 1 of Cycle (C) 1 of maintenance treatment.
Study: NCT05894239
Drug: Phesgo
Normalized name: Phesgo
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phesgo will be administered to participants subcutaneously every 3 weeks (Q3W) on D1 of each 21-day cycle.
Study: NCT06040086
Drug: Tozorakimab
Normalized name: TOZORAKIMAB
DrugBank: MEDI3506 (DB16473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously tozorakimab and placebo throughout the study.
Study: NCT06633016
Drug: ABX-002
Normalized name: ABX-002
DrugBank: ABX-002 (DB18157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABX-002 oral solution in 1-mL cyclic olefin polymer prefilled syringes, taken on an empty stomach first thing in the morning followed by 240 mL (8 oz) of water.
Study: NCT05885763
Drug: Difelikefalin Injection
Normalized name: difelikefalin Injection
DrugBank: Difelikefalin (DB11938)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants receive Difelikefalin three times a week (0,5 micrograms/kg dry body weight). Difelikefalin is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
Study: NCT06345339
Drug: Armour Thyroid
Normalized name: Armour Thyroid
DrugBank: Thyroid, porcine (DB09100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule or Tablet
Study: NCT06649864
Drug: Autologous adipose derived mesenchymal stromal cells (AMSC)
Normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells
DrugBank: Autologous adipose derived mesenchymal stromal cells (DB17925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adipose derived autologous mesenchymal stromal cells; \[\~500,000 cells/cm2\] will be applied once to the biliary anastomosis using approximately 3-5 million cells in 5ml Lactated Ringer solution.
Study: NCT05305664
Drug: Pelacarsen (TQJ230) 80 mg s.c.
DrugBank: Pelacarsen (DB16284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelacarsen (TQJ230) 80 mg s.c. Q4W
Study: NCT04802759
Drug: Giredestrant
Normalized name: Giredestrant
DrugBank: Giredestrant (DB19125)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression
Study: NCT04802759
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 150 mg orally twice a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression
Study: NCT04802759
Drug: Ipatasertib
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression
Study: NCT04802759
Drug: Inavolisib
Normalized name: Inavolisib
DrugBank: Inavolisib (DB15275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
Study: NCT04802759
Drug: Ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 600 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression
Study: NCT04802759
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
Study: NCT04802759
Drug: Samuraciclib
Normalized name: Samuraciclib
DrugBank: Samuraciclib (DB16061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
Study: NCT04802759
Drug: PH FDC SC
Normalized name: PH-284
DrugBank: PH-284 (DB05452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: On Day 1 of Cycle 1 (1 cycle is 21 days), pertuzumab and trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) will be administered SC as a fixed dose formulation of 1200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase. On Day 1 of Cycles 2 and beyond, PH FDC SC will be administered SC once every 21 days as a fixed dose of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase.
Study: NCT04802759
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 125 mg orally once a day on Days 1-21 during each 28-day cycle until unacceptable toxicity or disease progression
Study: NCT04802759
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 840 mg by intravenous (IV) infusion on Days 1 and 15 each 28-day cycle.
Study: NCT06287619
Drug: Monoferric Injectable Product
Normalized name: Monoferric Injectable Product
DrugBank: Ferric sulfate (DB11171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferric derisomaltose will be prepared by an unblinded research pharmacist as per standard of care procedures. Specifically, 10 mL (containing 1000 mg ferric derisomaltose) will be diluted in 100 mL of sterile 0.9% sodium chloride solution and drawn up into blinded syringes and tubing. The 1000 mg doses of ferric derisomaltose will be administered by a bedside nurse over 60 minutes via an infusion pump through a dedicated IV.
Study: NCT05261581
Drug: NSAID
Normalized name: Ansaid
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drugs (NSAIDs) are medicines that are widely used to relieve pain, reduce inflammation.
Study: NCT06355310
Drug: Empagliflozin 10 MG
Normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will take a 10 mg oral tablet of empagliflozin, an orally-active inhibitor of sodium-glucose co-transporter 2 (SGLT2)
Study: NCT06103227
Drug: Prednisone 5Mg
Normalized name: PREDNISONE 5MG TAB
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone administered for three weeks. If pregnant women weighs less than 90 kg , she will receive prednisone on altering days instead of every morning for pregnant women weighing more than 90 kg.
Study: NCT06393465
Drug: Tafamidis
Normalized name: Tafamidis
DrugBank: Tafamidis (DB11644)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 61 milligrams under real world conditions
Study: NCT05881265
Drug: Chidamide+venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chidamide 30mg BIW x 4 weeks; Venetoclax 100mg D1, 200mg D2 and 400mg D3-28
Study: NCT05531565
Drug: Litifilimab
Normalized name: Litifilimab
DrugBank: Litifilimab (DB18864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT05816694
Drug: NAB-Paclitaxel plus Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NAB-Paclitaxel will be administered as 125 mg/m2 IV infusion on Day 1 、Day8 of each 3-week cycle. Cisplatin will be administered as 75 mg/m2 IV infusion on Day 1 of each 3-week cycle. Patients will receive maximum of 4 cycles if they do not meet the criteria for removal from the study.
Study: NCT04895436
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral tablet
Study: NCT04895436
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (IV) infusion
Study: NCT06117436
Drug: Cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol 100 MG oral tablet once daily antiplatelet, Selenium 200mcg tablet once daily, anti oxidant
Study: NCT06117436
Drug: Selenium
Normalized name: Selenium
DrugBank: Selenium (DB11135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium 200 mcg oral tablet once daily
Study: NCT06116136
Drug: pembrolizumab 200 mg (KEYTRUDA ®)
Normalized name: pembrolizumab Injection [Keytruda]
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will be treated with 200 mg of pembrolizumab via intravenous (IV) infusion every 3 weeks (Q3W).
Study: NCT06238921
Drug: Zimberelimab
Normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One week +/- 4 days following receipt of SRS, zimberelimab 360 mg IV will be administered. This will be followed by zimberelimab 360 mg IV every 3 weeks.
Study: NCT06238921
Drug: Sacituzumab govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: SG will be administered on days 1 and 8 (10 mg/kg) of 21 day treatment cycles. This will be one week +/- 4 days following receipt of SRS for the first dose.
Study: NCT06564038
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Acalabrutinib tablet will be administered orally twice daily.
Study: NCT06564038
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone will be administered either oral or IV infusion as per standard of care.
Study: NCT06564038
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab will be administered as IV infusion as per standard of care.
Study: NCT06564038
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine will be administered as IV infusion as per standard of care.
Study: NCT06208306
Drug: Itepekimab (SAR440340)
Normalized name: Itepekimab
DrugBank: Itepekimab (DB16206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution for injection in pre-filled syringe Route of administration:subcutaneous
Study: NCT05936359
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rux will be administered according to Prescribing Information/SmPC.
Study: NCT06408259
Drug: Ozanimod
Normalized name: Ozanimod
DrugBank: Ozanimod (DB12612)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT06408259
Drug: Fingolimod
Normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT05251259
Drug: Atuliflapon
Normalized name: Atuliflapon
DrugBank: Atuliflapon (DB19029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomised participants will receive Atuliflapon
Study: NCT06560632
Drug: RP-3467 at assigned dose and schedule
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible participants will be treated with escalating doses of RP-3467 monotherapy
Study: NCT06087406
Drug: Imvotamab
Normalized name: Imvotamab
DrugBank: Imvotamab (DB17331)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT06389136
Drug: Upadacitinib Dose A
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral tablet
Study: NCT06389136
Drug: Dupilumab Dose A
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous (SC) injection
Study: NCT06389136
Drug: Upadacitinib Dose B
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral tablet
Study: NCT04789070
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus is a currently licensed drug primarily used for immunosuppression post-kidney transplantation to prevent organ rejection. Sirolimus was initially considered as a treatment in IBM for its immunosuppressive action and beneficial effects in an experimental myositis mouse model.(11) Transfer of effector T cells from affected to healthy animals resulted in myositis, but the presence of Treg cells were protective against development of myositis. As Sirolimus, which acts to deplete effector T cells but preserving the Treg cells, was effective in this mouse model of myositis, it was therefore postulated that it may also be effective in IBM, not only for its effects on effector T cells and Treg cells, but also for its additional effects on protein degradation.
Study: NCT06319170
Drug: Olanzapine Extended Release
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Powder and vehicle for injectable suspension
Study: NCT06319170
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IntraMuscular Injection
Study: NCT06583070
Drug: Targeted and immunotherapy
Normalized name: brompheniramine
DrugBank: Brompheniramine (DB00835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Targeted and immunotherapy
Study: NCT05580770
Drug: Mirdametinib
Normalized name: Mirdametinib
DrugBank: Mirdametinib (DB07101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirdametinib administered orally
Study: NCT05580770
Drug: BGB-3245
Normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGB-3245 administered orally
Study: NCT06456515
Drug: Regorafenib and Sintilimab in combination with electroacupuncture
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib, take for 2 weeks and stop for 1 week; Sintilimab, intravenous, every 3 weeks; Electroacupuncture was performed 1 day before, on the day of, and on the 2nd day after each cycle of Sintilimab administration, and patients completed 3 treatments in week 1, followed by 1 treatment per week for 2 weeks, with 5 treatments per dosing cycle.
Study: NCT05019885
Drug: Ketamine Hydrochloride
Normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three times a week (M, W, F) for 2 consecutive weeks.
Study: NCT06511037
Drug: Pafolacianine (CYTALUX) with intraoperative fluorescent near-infrared (NIR) imaging
DrugBank: Pafolacianine (DB15413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05185583
Drug: Methylphenidate Hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive twice daily doses of Methylphenidate Hydrochloride four hours apart. There will be three dosage schedules, determined based on three weight ranges (20-30kg; 30-40kg; ≥40kg). For children weighing 20-30kg, the maximum daily dose will be 20mg. For children weighing 30-40kg, the maximum daily dose will be 30mg. For children weighing ≥40kg, the maximum daily dose will be 40mg.
Study: NCT02522611
Drug: Resiniferatoxin
Normalized name: resiniferatoxin
DrugBank: Resiniferatoxin (DB06515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resiniferatoxin (RTX) is an ultrapotent agonist analog of capsaicin that targets a receptor expressed on specific dorsal root sensory ganglia (DRG) neurons and is expected to reduce pain within the targeted zone.
Study: NCT06486051
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m\^2/day IV for three consecutive days
Study: NCT04708054
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04708054
Drug: Cladribine
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04708054
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04708054
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT04708054
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT06240754
Drug: Enasidenib
Normalized name: Enasidenib
DrugBank: Enasidenib (DB13874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Provided by BMS.
Study: NCT04728711
Drug: ADX-629
Normalized name: ADX 102
DrugBank: Reproxalap (DB16688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADX-629, 600 mg administered orally twice daily (PO bid) for a minimum of 1 week
Study: NCT05662098
Drug: Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive an individualized PK hydroxyurea assessment. Participants for whom the PK-process successfully generates a dose in the predicted treatment range of 15-35 mg/kg/day, will start on that personalized dose. Participants for whom the process does not generate a starting hydroxyurea dose in the predicted treatment range, due to potential pitfalls in lab draws, serum storage, sample processing, or hydroxyurea analysis, will start at a default dose of 20.0 ± 2.5 mg/kg/day. For all participants, the hydroxyurea dose will be adjusted as needed based on blood counts to establish the optimal dose. Where necessary, a weekly dosing average will be determined, so that treatment can occur solely with locally available and affordable 500mg hydroxyurea capsules.
Study: NCT04279847
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib will be administered twice a day using the dose described for each Cohort in the protocol for Part 2.
Study: NCT06412198
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by IV
Study: NCT06412198
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given by IV
Study: NCT06412198
Drug: Adagrasib
Normalized name: Adagrasib
DrugBank: Adagrasib (DB15568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by PO
Study: NCT06570798
Drug: Inebilizumab
Normalized name: INEBILIZUMAB
DrugBank: Inebilizumab (DB12530)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous (IV) Infusion
Study: NCT06570798
Drug: Blinatumomab
Normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SC Injection
Study: NCT05606341
Drug: CpG1018
Normalized name: hepatitis B vaccine/CpG1018/PF 20 mcg/0.5 mL INTRAMUSC VIAL (ML)
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc.
Study: NCT05606341
Drug: CpG1018
Normalized name: hepatitis B vaccine/CpG1018/PF 20 mcg/0.5 mL INTRAMUSC VIAL (ML)
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc.
Study: NCT05606341
Drug: CpG1018
Normalized name: hepatitis B vaccine/CpG1018/PF 20 mcg/0.5 mL INTRAMUSC VIAL (ML)
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc.
Study: NCT06506422
Drug: Empagliflozin 10 MG
Normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10mg Empagliflozin daily for 12 weeks
Study: NCT05259839
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral; Tablet or IV Infusion
Study: NCT05259839
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral; Capsule
Study: NCT05259839
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral; Capsule
Study: NCT05259839
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous Injection (SC)
Study: NCT04268277
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg concentrate for solution for infusion
Study: NCT04268277
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg/ 4mL concentrate for solution for infusion
Study: NCT05833724
Drug: Chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Subjects will receive a single dose of 30 mg chidamide. Twice a week.
Study: NCT06408168
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given by PO
Study: NCT06408168
Drug: Repotrectinib
Normalized name: Repotrectinib
DrugBank: Repotrectinib (DB16826)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV
Study: NCT05588843
Drug: SAR443122
Normalized name: SAR443122
DrugBank: SAR443122 (DB16492)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule
Study: NCT04041232
Drug: PBA
Normalized name: PBA
DrugBank: Phenylbutyric acid (DB06819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol phenylbutyrate (PBA) is a triglyceride that consists of three molecules of phenylbutyrate linked to a glycerol backbone. It is a nitrogen-binding agent that has been approved by the Food and Drug Administration (FDA) for the treatment of urea cycle disorders. Oral supplementation of PBA demonstrated no severe side effects, and are found to be therapeutically effective in reducing ER stress. Patients will be instructed to take three doses of PBA per day at equally divided time intervals and rounded up to the nearest 0.5 mL. The total dose of PBA will be 4.5 to 11.2 mL/m2/day (5 to 12.4 g/m2/day) and will not exceed 17.5 mL/day (19 g/day).